Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SLC-3010
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : GenScript ProBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SLC-3010 selectively stimulates anti-tumor immune response and the efficacy of SLC-3010 in eradication of various types of tumor was thoroughly demonstrated through various in vitro and in vivo experiments.
Brand Name : SLC-3010
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 23, 2022
Lead Product(s) : SLC-3010
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : GenScript ProBio
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?